SAN
DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial
stage biotechnology company, today announced that the company
granted equity awards to 3 new employees with a grant date of
September 1, 2023, as equity
inducement awards outside of the company's 2022 Equity Incentive
Plan (but under the terms of the company's Inducement Plan) and
material to the employee's acceptance of employment with the
company. The equity awards were approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase
25,531 shares of Mirati's common stock, and in the aggregate,
15,089 restricted stock units ("RSUs"). The options have an
exercise price of $37.75 per share,
which is equal to the closing price of Mirati's common stock on
September 1, 2023, (the "Grant
Date"). One-fourth of the shares underlying the employee options
will vest on the one-year anniversary of the Grant Date and
thereafter 1/48th of the shares underlying the employee options
will vest monthly, such that the shares underlying the options
granted to the employee will be fully vested on the fourth
anniversary of the Grant Date, subject to the employee's continued
employment with Mirati on such vesting dates. Each RSU will vest as
to 25% of the shares underlying the RSU award on the first
anniversary of the Grant Date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to the
employee's continued employment on each vesting date.
About Mirati Therapeutics, Inc.®
Mirati Therapeutics, Inc. is a commercial stage biotechnology
company whose mission is to discover, design and deliver
breakthrough therapies to transform the lives of patients with
cancer and their loved ones. The company is relentlessly focused on
bringing forward therapies that address areas of high unmet need,
including lung cancer, and advancing a pipeline of novel
therapeutics targeting the genetic and immunological drivers of
cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us on Twitter, LinkedIn, and
Facebook.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301918173.html
SOURCE Mirati Therapeutics, Inc.